OncoMatch/Clinical Trials/NCT05884333
Cord Blood Transplant in Adults With Blood Cancers
Is NCT05884333 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cord blood graft and Conditioning Chemotherapy for acute myelogenous leukemia (aml).
Treatment: Conditioning Chemotherapy · Cord blood graft — Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: BCR t(9;22)
Presence of any high-risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality
Allowed: TCF3 t(1;19)
Presence of any high-risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality
Allowed: KMT2A (MLL) t(4;11) or other MLL rearrangements (11q23)
Presence of any high-risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality
Prior therapy
Cannot have received: checkpoint inhibitor
Prior checkpoint inhibitors/ blockade in the last 12 months.
Cannot have received: stem cell transplant
Exception: Two prior stem cell transplants of any kind
Two prior stem cell transplants of any kind.
Cannot have received: autologous stem cell transplant
Exception: within the preceding 12 months
One prior autologous stem cell transplant within the preceding 12 months.
Cannot have received: allogeneic transplantation
Prior allogeneic transplantation.
Cannot have received: radiation therapy
Exception: Prior involved field radiation therapy that would preclude safe delivery of 400cGy TBI in the opinion of Radiation Oncology.
Prior involved field radiation therapy that would preclude safe delivery of 400cGy TBI in the opinion of Radiation Oncology.
Lab requirements
Blood counts
ANC > 0.2 (growth factor supported if necessary) at transplant work-up; Albumin > 3.0
Kidney function
Calculated creatinine clearance > 70 ml/min
Liver function
Bilirubin < 1.5 mg/dL (unless benign congenital hyperbilirubinemia or hemolysis); ALT < 3 x upper limit of normal (ULN)
Cardiac function
Left ventricular ejection fraction (MOD-bp) > 50%
Calculated creatinine clearance > 70 ml/min. Bilirubin < 1.5 mg/dL (unless benign congenital hyperbilirubinemia or hemolysis). ALT < 3 x upper limit of normal (ULN). Pulmonary function: Spirometry (FVC and FEV1) and corrected DLCO) > 60% predicted. Left ventricular ejection fraction (MOD-bp)> 50%. Albumin > 3.0. Hematopoietic Cell Transplantation Comorbidity index (HCT-CI) ≤5.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify